ImmunoPrecise Antibodies Ltd. IPA
Oct 20, 2025, 2:54 PM EDT
- Market cap
- 12.39M
- Revenue (ttm)
- 24.09M
- Profit margin
- -115.22%
- EPS (ttm)
- -0.75
- Shares out
- 31.06M
- Forward P/E
- -2.49
- Volume
- 55.66K
- Avg volume
- 558.86K
- Open
- 1.65
- Previous close
- 1.62
- Day's range
- 1.56 – 1.65
- 52-week range
- 0.325 – 2.60
- Beta
- 0.27
- Analysts
- Buy
- Price target
- 5.00 (+208.6%)
- Earnings date
- Sep 16, 2024
Key statistics
- Enterprise value
- 23.90M
- PEG ratio
- 0.00
- Price / sales
- 0.51
- Price / book
- 0.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -7.50%
- Free cash flow
- -808.50K
- Total cash
- 3.91M
- Total debt
- 16.10M
- Return on equity
- -64.04%
- Short % of float
- 2.41%
- 50-day average
- 0.452
- 200-day average
- 0.882795
Analyst view
Consensus: buy
- Target (low)
- 3.00
- Target (mean)
- 5.00
- Target (high)
- 7.00
- Strong buy2
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Sep 16, 2024
Expected Sep 16, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 10, 2024 | Oct 1, 2024 | -0.05 | -0.07 | -0.02 | -40.00% |
| Sep 16, 2024 | Jul 1, 2024 | -0.09 | — | — | — |
| Sep 16, 2024 | Jul 1, 2024 | -0.09 | -0.11 | -0.02 | -22.22% |
| Jul 29, 2024 | Apr 1, 2024 | -0.10 | — | — | — |
| Jul 29, 2024 | Apr 1, 2024 | -0.10 | -0.52 | -0.42 | -420.00% |
| Mar 14, 2024 | Jan 1, 2024 | -0.08 | -0.08 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2024 | Benchmark | main | Speculative Buy | Speculative Buy |
| Jul 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 15, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Mar 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd., a biotechnology company, leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; peptide production for subsequent antibody discovery campaign; B cell select platform, which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. In addition, it provides phage display, a custom immune library; CAR development, an adaptable antibody, which allows the inclusion of functional data early in the screening funnel; antibody sequencing; and assay development. Further, it offers a profiling toolset for antibody lead candidates; and in vitro analytical tools for the study of quality attributes. Additionally, it provides LucinaTech, an antibody humanization to identify framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody chimerization for cloning and production of antibody domain; Eurofins preclinical services; hybrid service model designed to reduce time and risk with custom applications; breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts; and protein manufacturing services. The company is headquartered in Victoria, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- ipatherapeutics.com
News
Institutional Property Advisors Brokers $204.75 Million Sale of 1,035-Bed Student Housing Property in Northern California 
IPA Capital Markets Arranges $50 Million in Financing for 18-Property Industrial Portfolio 
IPA Capital Markets Arranges $40.3 Million Financing for 312-Unit Birwood Heights in San Antonio 
BrewDog Claims London's Summer Park Season with ‘Park IPA' 
Marcus & Millichap's Institutional Property Advisors Division Brokers $90.5 Million Sale of 400 Multifamily Units in West Palm Beach 
The Biology Came First. 
Atlas AI Labs to Launch First Ever Permissionless Asset-Backed Token from Dubai 
Blue Point Brewing Launches Magic Hour IPA—A Bright, Tropical 6% ABV Sipper for Golden Hour 
SweetWater Introduces Big Trip Double IPA: A Bold New Craft Beer 
Dogfish Head Puts January's Pressures on Ice with “30 Minute Time Bank” Pop-Up
Your note
Sign in to keep a note on IPA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ingalls & Snyder | 5.41% | 1,558,892 | 622.00K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.21% | 60,300 | 24.06K | Sep 29, 2024 |
| Bank of Montreal /CAN/ | 0.20% | 57,807 | 23.06K | Sep 29, 2024 |
| Northern Trust Corporation | 0.18% | 50,730 | 20.24K | Sep 29, 2024 |
| Cibc World Markets, Inc. | 0.14% | 41,200 | 16.44K | Sep 29, 2024 |
| Gradient Capital Advisors, LLC | 0.09% | 26,808 | 10.70K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.06% | 17,484 | 6.98K | Oct 30, 2024 |